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Sestrin2 (SESN2), a highly conserved stress-inducible metabolic protein, is known to repress reactive oxygen species (ROS)
and provide cytoprotection against various noxious stimuli including genotoxic and oxidative stress, endoplasmic reticulum
(ER) stress, and hypoxia. Studies demonstrate that the upregulation of Sestrin2 under conditions of oxidative stress
augments autophagy-directed degradation of Kelch-like ECH-associated protein 1 (Keap1), which targets and breaks down
nuclear erythroid-related factor 2 (Nrf2), a key regulator of various antioxidant genes. Moreover, ER stress and hypoxia
are shown to induce Sestrins, which ultimately reduce cellular ROS levels. Sestrin2 also plays a pivotal role in metabolic
regulation through activation of the key energy sensor AMP-dependent protein kinase (AMPK) and inhibition of
mammalian target of rapamycin complex 1 (mTORC1). Other downstream effects of Sestrins include autophagy activation,
antiapoptotic effects in normal cells, and proapoptotic effects in cancer cells. As perturbations in the aforementioned
pathways are well documented in multiple diseases, Sestrin2 might serve as a potential therapeutic target for various
diseases. Thus, the aim of this review is to discuss the upstream regulators and the downstream effectors of Sestrins and
to highlight the significance of Sestrin2 as a biomarker and a therapeutic target in diseases such as metabolic disorders,
cardiovascular and neurodegenerative diseases, and cancer.
1. Introduction
Sestrins (SESN) are highly conserved proteins with pleiotro-
pic biological functions and are upregulated in cells under
stressful conditions such as DNA damage, hypoxia, starva-
tion, growth factor depletion, radiation, and oxidative stress
[1, 2]. Following their induction, Sestrins protect cells against
genotoxic and oxidative stress and are, thus, named as stress-
inducible metabolic regulators [1]. Sestrin proteins comprise
of three distinct family members, characterized by specific
protein-coding genes such as SESN1, SESN2, and SESN3,
which share nearly 50% identical amino acid sequences [1,
3]. Despite their genetic homology, identification of the spe-
cific biochemical functions of each Sestrin was challenging, as
their protein structure contains an atypical structural
domain. The distant sequence homology of Sestrins to bacte-
rial oxidoreductases led to the discovery of their antioxidant
properties in mammalian cells [1]. SESN1, also known as
p53-activated gene 26 (PA26) because it is regulated by
tumor-suppressor protein (p53), has been recognized as
one of the growth arrest and DNA damage-inducible genes
(GADD) [3]. SESN2, a homolog of PA26, is referred to as
hypoxia-inducible gene 95 (Hi95), owing to its induction
under hypoxic conditions, albeit other cytotoxic events such
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as oxidative stress and DNA damage also induce SESN2
levels [3–5]. SESN3 is as a novel PA26 structure-related gene
inducible by the forkhead box O (FoxO) family of transcrip-
tion factors [6].
2. Sestrins: Isoforms, Their Regulation, and
Cellular Effects
As stress-inducible metabolic regulators, Sestrins help cells to
adapt to various stress stimuli via multiple mechanisms
including activation of catabolic reactions, cessation of ana-
bolic activities, and initiation of cell repair mechanisms to
maintain cellular homeostasis [1]. Specifically, Sestrins play
a cytoprotective role via decreasing the levels of reactive oxy-
gen species (ROS) resulting from oxidative and genotoxic
stress [3]. The tumor suppressive p53 gene, which regulates
many stress-activated transcriptional factors, is critical for
the expression of Sestrin1 following oxidative stress [1]. In
addition to p53, the nuclear factor (erythroid-derived 2-) like
2 (Nrf2) and activator protein 1 (AP-1) are requisite for
Sestrin2 stimulation; correspondingly, the AP-1 and the
forkhead box O (FoxO) transcriptional proteins FoxO1 and
FoxO3 are essential for Sestrin3 induction [6, 7], as shown
in Table 1. Moreover, the inhibition of ROS by Sestrins might
be elicited directly through their enzymatic activity (peroxir-
edoxin) or by activation of Nrf2, a master key regulator of
various antioxidant genes [5, 7]. Therefore, Sestrins prevent
the accumulation of ROS through its antioxidant properties
via multiple signaling pathways.
Parallel to its redox-regulating actions, Sestrins inhibit
mammalian target of rapamycin complex 1 (mTORC1) activity
primarily through the activation of adenosinemonophosphate-
dependent protein kinase (AMPK) [1, 6, 21]. The activation of
AMPK by Sestrins might be via direct physical association or
by indirect transcriptional regulation. Apart from its actions
mediated through AMPK, Sestrins act as inhibitors of GTPase-
activating protein for Rag (Rag GTPases), which are important
formTORC1 activity.Through these concerted actions, Sestrins
inhibit mTORC1 and consequently reduce protein synthesis
during unfolded protein response (UPR) and protect cells
against endoplasmic reticulum (ER) stress [22].
Sestrins also play a vital role in metabolic homeostasis via
upstream regulation of the mTORC1 and AMPK signaling
pathways, which are critical for energy and nutrient sensing
in cells. Inactivation of Sestrin genes result in various cellular
and metabolic pathologies, such as oxidative damage,
mitochondrial dysfunction, fat accumulation, muscle degen-
eration, and accelerated progression of diabetic complica-
tions [23–25]. Hence, it is critical to understand the role of
Sestrins in the modulation of pathophysiologic mechanisms
such as oxidative stress, autophagy, ER stress, apoptosis,
and hypoxia, which are closely linked to altered mTOR/
AMPK signaling in cells.
3. Upstream Pathways and Mechanisms that
Modulate Sestrins
3.1. Oxidative Stress.Oxidative stress occurs when there is an
imbalance between the generation of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) and their scav-
enging mechanisms. Sestrin family of proteins is one of the
several antioxidant defense mechanisms, which primarily
gets stimulated under oxidative stress, although other nox-
ious stimuli could induce Sestrins [5, 26, 27]. High levels of
ROS stimulate a series of antioxidant genes mainly through
activation of the antioxidant response elements (AREs)
[28]. Nuclear factor (erythroid-derived 2-) like 2 or NF-E2-
related factor-2 (Nrf2) is an important transcriptional factor
(from the family of basic leucine zipper (bZIP) proteins) that
regulates the expression of various antioxidant genes through
binding to AREs [7, 28]. Under normal conditions, Nrf2 is
localized in cytosol with its repressor Kelch-like ECH-
associated protein 1 (Keap1) and subjected to ubiquitination
and proteasomal degradation via Cul3-based E3 ligase. Oxi-
dative stress dissociates the repressor molecule Keap1 from
Nrf2, and facilitates the nuclear translocation of Nrf2 and
its binding and activation of AREs [7]. Nrf2 is ubiquitously
expressed in mammalian cells and plays an essential role as
a cytoprotector under severe stress-related conditions [28].
A study by Shin et al. [28] demonstrated the central role
of Nrf2-ARE system in the regulation of Sestrin2 expression.
Specifically, the study revealed that Nrf2 activators such as
tert-butylhydroquinone and sulforaphane upregulate the
expression of Sestrin2 mRNA in a dose- and time-
dependent manner. The mechanism by which Sestrin2
activates Nrf2 expression was unveiled in a study by Bae
et al. [7]. The study revealed that the antioxidant effects of
Sestrin2 are mediated by the degradation of Keap1 through
p62-dependent autophagy and consequent activation of
Nrf2. Furthermore, a study by Kim et al. [29] demonstrated
that the injection with Ad-SESN2 (recombinant adenovirus
encoding Sestrin2) in mice not only inhibits
Table 1: Sestrin family of proteins, their regulators, and cellular effects.
Isoforms of Sestrin Regulators Effects on cell signaling
Sestrin1 (SESN1) p53
(i) ROS inhibition via upregulation of antioxidants [1, 3, 7]
(ii) Activation of AMPK pathway [1, 3, 8]
(iii) Downregulation of mTOR pathway [1, 3, 6, 9]
(iv) Induction of autophagy [1, 3, 7, 10]
(v) Protective role against cancer [11–13], metabolic and cardiovascular
diseases [14–16], and neurodegenerative disorders [17–20]
Sestrin2 (SESN2)
p53
Nrf2
AP-1
Sestrin3 (SESN3)
AP-1
FoxO1
FoxO3
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acetaminophen-induced oxidative stress and inflammatory
response but also prevents acetaminophen-induced liver
toxicity and associated mortality.
Cancer cells, unlike normal cells, favor conditions of
oxidative stress and fuel ROS to support their high cell
proliferation and to promote mutations, ultimately result-
ing in genomic instability and cell survival. Despite the
high levels of ROS, most forms of cancer are associated
with significant downregulation of Sestrin2 [4, 12, 22].
Conversely, the induction of Sestrin2 in various cancer
cell lines has been shown to curb oxidative stress and
slow tumorigenesis [3, 4, 11]. Together, these findings
underscore that the antioxidant effects of Sestrin2 confer
cytoprotection, prevent organ damage, and abrogate tumori-
genesis as shown in Figure 1.
3.2. Endoplasmic Reticulum (ER) Stress. Endoplasmic reticu-
lum (ER) stress occurs when unfolded proteins get accumu-
lated within the lumen of ER due to adverse physiologic
conditions. The three ER transmembrane enzymes, protein
kinase RNA-like endoplasmic reticulum kinase (PERK),
inositol-requiring enzyme 1 (IRE1), and activating transcrip-
tion factor 6 (ATF6), which monitor the health of ER, play a
crucial role in the remediation of ER stress via triggering an
unfolded protein response (UPR) [30]. The UPR is recog-
nized as an integrated signal transduction mechanism, whose
primary objective is to restore ER homeostasis via diverse but
interconnected mechanisms. All three pathways, PERK,
IRE1, and ATF6, ultimately evoke an adaptive response
through upregulation of the key ER chaperones, repression
of protein translation, and stimulation of protein degradation
by ER-associated degradation (ERAD) mechanism. When
ER stress continues for prolong periods, the UPR machinery
preferentially stimulates apoptotic pathways and leads to cell
death [30, 31].
Several studies have demonstrated the upregulation of
Sestrin2 under ER stress conditions [30–33]; however, the
exact mechanism by which ER stress induces Sestrin2 expres-
sion is poorly understood. For instance, Park et al. [31]
demonstrated that the induction of Sestrin2 in response to
palmitate-induced ER stress in hepatocytes occurs through
PERK-c/EBPβ-mediated signal transduction mechanism.
Consistent with these findings, a study in cancer cells by
Bruning et al. [32] showed that the induction of Sestrin2 is
dependent on the PERK via activating transcription factor
4 (ATF4). A recent study by Saveljeva et al. [33] revealed
that mouse embryo fibroblasts (MEFs) deficient in PERK
or X-box-binding protein-1 (XBP1, a downstream marker
of IRE1) are unable to induce Sestrin2 expression in
response to ER stress. Similarly, knockdown of XBP1 in can-
cer cell lines—HCC1806 and MCF7—prevented Sestrin2
induction that occurs in response to thapsigargin- and
methotrexate-mediated ER stress. Together, these studies
indicate that the upregulation of Sestrin2 under ER stress
is dependent on both PERK and IRE1/XBP1 transduction
pathways [33].
Recently, a study by Ding et al. [30] demonstrated the
upregulation of Sestrin2 expression through ATF4 and Nrf2
transcription factor under ER stress induced by glucose
starvation. The study further demonstrated that both tran-
scription factors (ATF4 and Nrf2) get stimulated through
the PERK1 pathway of UPR and directly bind to Sestrin2
promoter. Interestingly, the induction of Sestrin2 by ATF4
and Nrf2 occurs through a mechanism that is independent
of p53, the master regulator of Sestrin2 induction upon
DNA damage. Hence, it could be proposed that the activation
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Figure 1: Role of Sestrin2 in redox balance. Cellular homeostasis is achieved by counteracting the production of reactive oxygen species
(ROS) with antioxidant molecules. Hypoxia, starvation, cancer, and genotoxic stress induce oxidative stress in cells and tip the cellular
redox balance towards a pro-oxidant state. Sestrins help cells to restore their normal redox state through various mechanisms including
stabilization of Nrf2 via the inhibition of Keap1 and recycling of peroxiredoxin (Prx). Keap1: Kelch-like ECH-associated protein 1; Nrf2:
nuclear factor (erythroid-derived 2-) like 2.
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of Sestrin2 occurs via two mechanisms: first, through p53 in
response to DNA damage and, second, by UPR-mediated
activation of ATF4 and Nrf2 [30]. The ER stress pathways
that upregulate Sestrin2 are shown in the Figure 2.
3.3. Hypoxia. Low-oxygen tension or hypoxia is one of the
prominent stimuli that is known to activate the expression
of Sestrin2. In fact, Sestrin2 was first isolated as a gene
activated in human neuroblastoma cells under hypoxia
conditions [5, 9]. For example, exposure of cancer cells to
hypoxia upregulates both Sestrin1 and Sestrin2. However,
unlike Sestrin1, the activation of Sestrin2 is independent of
p53 and is mainly due to energy deprivation secondary to
prolonged hypoxia [1, 5]. Nevertheless, some exceptions do
exist as Sestrin2 could be activated via mechanisms depen-
dent [5] as well as independent [34] of hypoxia-inducible
factor (HIF-1) as shown in the Figure 2. Moreover, the mech-
anism by which certain drugs and chemicals such as metfor-
min and 2-deoxyglucose, which stimulate hypoxia, activate
Sestrin2 is yet to be deciphered [35].
Shi et al. [17] studied the relationship between HIF-1α
protein and recombinant human Sestrin2 in both severe
and moderate hypoxic-ischemic (HI) injuries in neonatal
rats. Data from the study suggests a distinct and profound
neuronal upregulation of Sestrin2 by HIF-1α under severe
HI injury as compared to moderate HI injury. In addition,
the HIF-1α-mediated induction of Sestrin2 in neurons was
demonstrated to attenuate blood-brain barrier (BBB) perme-
ability through suppression of vascular endothelial growth
factor (VEGF) in neonatal rats subjected to severe HI injury
[17]. Similarly, Sestrin2 activation was shown to inhibit
angiogenesis and VEGF production in a cancer xenograft
model [18]. Furthermore, the hypoxia-mediated upregula-
tion of Sestrin2 also serves to counteract ROS generation in
cells. This evidence was revealed in a study by Essler et al.
[36], which evaluated the significance of hypoxia and nitric
oxide (NO) on the transcription regulation of various genes
involved in peroxide signaling pathway using RAW 264.7
cells (a macrophage cell line). Findings from the study dem-
onstrate that hypoxia and NO upregulate Sestrin2 in a HIF-
1α-dependent manner, and the resultant activated Sestrin2
augments peroxide defense by preventing peroxiredoxins
from sulfinylation [36]. Therefore, Sestrin2 not only serves
as a molecule to integrate the signals of hypoxia and oxidative
stress but also acts as a defense mechanism to combat against
cellular stress.
4. Downstream Pathways and Mechanisms
Modulated by Sestrins
4.1. AMP-Activated Protein Kinase (AMPK) Activation and
mTORC1 Inhibition. The mechanistic/mammalian target of
rapamycin (mTOR) is a serine-threonine protein kinase
initially discovered in yeast mutants that are resistant to the
growth inhibitory actions of rapamycin and was soon after
cloned in mammalian cells. mTOR comprises of two distinct
multiprotein complexes: the mechanistic target of rapamycin
complex 1 (mTORC1), which is sensitive to rapamycin, and
the mTORC2, which is insensitive to rapamycin. The
mTORC1 protein kinase is regarded as a “master regulator”
as it responds to various stimuli including growth factors,
oxidative stress, and alterations in energy levels [37, 38]. Stim-
ulation ofmTORC1 leads to phosphorylation of two proteins,
p70 ribosomal protein S6 kinase (p70S6K) and 4E-binding
protein-1 (4EBP1), and ultimately results in increased protein
and lipid synthesis, cell proliferation, and/or survival [37, 38].
PersistentmTORstimulation is linked tovariousdiseases such
as diabetes, obesity, cardiovascular diseases, cancer, and
autoimmune disorders [38].
AMP-activated protein kinase (AMPK), an enzyme acti-
vated under the conditions of energy deficiency, serves as the
principal negative regulator of mTOR in cells. Studies indi-
cate that Sestrin2 inhibits mTOR activation in cells mainly
through the activation of AMPK and phosphorylation of
tuberous sclerosis 2 (TSC2) [9, 23]. Moreover, genetic silenc-
ing and knockdown of Sestrin2 in vitro and in vivo cause sus-
tained activation of mTOR signaling in multiple cell types
including liver, indicating the essential role of Sestrin2 on
mTOR inhibition. For instance, a study by Hamatani et al.
[39] demonstrated that silencing of Sestrin2 upregulates the
phosphorylation of mTORC1 downstream targets such as
p70S6K in parietal epithelial cells. Intriguingly, chronic acti-
vation of mTOR due to overnutrition in mice eventually
leads to the induction of Sestrin2 in multiple tissues includ-
ing liver and skeletal muscle [23]. Conversely, genetic
Endoplasmic 
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Figure 2: Upregulation of Sestrin2 under endoplasmic reticulum
stress, genotoxic stress, and hypoxia. UPR mediators play a
significant role in ER stress-mediated upregulation of Sestrin2.
Two of the three UPR mediators, IRE1 (via XBP1) and PERK
(through P-eIF2 and Nrf2), upregulate Sestrin2. Similarly,
independent of ER stress, p53 (in response to genotoxic stress)
and hypoxia also activate Sestrin2 expression. ATF4: activating
transcription factor 4; ATF6: activating transcription factor 6;
IRE1: inositol-requiring enzyme 1; NRF2: nuclear factor
(erythroid-derived 2-) like 2; P-eIF2: phosphorylated eukaryotic
initiation factor 2; PERK: protein kinase RNA-like endoplasmic
reticulum kinase; UPR: unfolded protein response; XBP1: X-box-
binding protein-1.
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ablation of Sestrin2 augments mTOR activation and aggra-
vates obesity-associated features such as glucose intolerance,
insulin resistance, and hepatosteatosis in mice [23]. Consis-
tent with the above findings, the inhibition of AMPK using
compound C was shown to upregulate Sestrin2 via induction
and accumulation of mitochondrial ROS [40].
An inverse modulation of mTOR and AMPK signaling by
Sestrin2 appears to be responsible for its neuroprotective
effects. For example, Shi et al. [41] revealed that the neuropro-
tective effects of Sestrin2 following hypoxic-ischemic enceph-
alopathy are mediated through modulation of AMPK and
mTOR signaling pathway. In addition, the study also demon-
strated that administration of recombinant human Sestrin2
significantly enhances neurological function besides reducing
cerebral infarction and brain atrophy. The critical role of
AMPK activation on the antioxidant properties of Sestrin2
was revealed in a study by Eid et al. [21]. The study demon-
strated that Sestrin2-mediated activation of AMPK pathway
also inhibits NADPH-dependent oxidase 4 (NOX4), conse-
quently, reducing cytosolic ROS produced by NOX4 oxidase
system [21]. The pathways that interconnect the regulation
of ROS and AMPK signaling pathways and their downstream
mediators are depicted in the Figure 3.
4.2. Autophagy. Autophagy is one of the cellular defense
mechanisms that directs aged and misfolded proteins for
lysosomal degradation and thereby protects cells from undue
stress and maladaptive cell signaling [42, 43]. A major
stimulus for autophagy activation in cells is the inhibition of
mTOR signaling and/or activation of AMPK through phos-
phorylation of autophagy-related protein (ATG) and unc-
51-like autophagy-activating kinase 1 (Ulk1) protein [44]. As
described earlier, Sestrin2 regulates mTORC1/AMPK signal-
ing pathway; accordingly, it is expected that the activation of
Sestrin2 would stimulate autophagy in cells. Indeed, Sestrin2,
in concerted action with several autophagy-related proteins
(ATG) and BCL2/adenovirus E1B 19kDa protein-interacting
protein 3 (BNIP3), has been shown to induce autophagy
[45]. Moreover, the inhibition of mTORC1 by Sestrin2 is
important for the p62 autophagy-mediated breakdown of
Kelch-like ECH-associated protein 1 (Keap1), the repressor
molecule that directs Nrf2 to proteasomal degradation [7].
Thus, autophagy activation is an essential requirement for
the antioxidant effects of Sestrin2—mediated by Nrf2 signa-
ling—to prevail during oxidative stress.
Furthermore, studies in cancer cells [10, 46] reveal that
the induction of autophagy by Sestrin2 is regulated by
c-Jun N-terminal kinase (JNK) pathway. Studies in nasopha-
ryngeal carcinoma cell lines by Zhang et al. [10] demonstrated
that stimulation of JNK pathway increases the expression of
Sestrin2, and this induction of Sestrin2 could be attenuated
by siRNA-mediated silencing of JNK pathway. Interestingly,
the JNK-mediated autophagy was inhibited following silenc-
ing of the expression of Sestrin2, which indicates that the
JNK-mediated autophagy induction in cancer cells occurs in
a Sestrin2-dependent manner. A recent study by Liang et al.
[46] in human bladder cancers unveiled the mechanism by
which JNKactivates Sestrin2 and stimulates autophagy in can-
cer cells. Findings from this study indicate that binding of JUN
(resulting from activation of JNK pathway) to the AP-1 bind-
ing site in the Sestrin2promoter region is critical for the induc-
tionofSestrin2andconsequent autophagyactivation incancer
cells. Taken together, Sestrin2 plays an important role in the
stimulation of autophagy [10, 46] and, hence, serves as amedi-
ator for cells to integrate the nutrient signals (AMPK and
mTOR) and signaling pathways such as JNK to modulate
autophagic response and promote the survival of normal but
the death of cancer cells.
4.3. Apoptosis. Programmed cell death, commonly referred to
as apoptosis, serves as a process to control cell growth and
development. Apoptosis is characterized by specific bio-
chemical and morphological changes including membrane
blebbing, cell shrinkage, nuclear condensation, chromo-
somal DNA fragmentation, and cleavage of intracellular
proteins by specific enzymes called caspases [39]. Numerous
studies have documented the antiapoptotic role of Sestrin2
in various cell types [41, 47]. A study in RAW264.7 cells
by Hu et al. [47] reported that exposure to oxidized low-
density lipoprotein (oxLDL) stimulates the expression of
Sestrin2 through JNK/c-Jun pathway and knockdown of
Sestrin2 promotes apoptosis. In correlation to these findings
in vitro, intranasal administration of recombinant human
Sestrin2 in neonatal rats subjected to hypoxic-ischemic
injury was shown to reduce neuronal apoptosis and improve
neurological function [41]. Thus, induction of Sestrin2
Sestrin
Pathologic stimuli 
AMPK
activation
mTOR activation
Autophagy
induction
Protein synthesis and
cell proliferation
TSC1/2
S6KULK1/ATG1 4EBP1
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Figure 3: Modulation of AMPK and mTOR pathway by Sestrins.
Activation of mTOR signaling induces reactive oxygen species
(ROS) generation, inhibits autophagy, and promotes protein
synthesis and cell proliferation. Sestrins downregulate mTOR
signaling pathway and activate AMPK signaling, which in turn
relieves autophagy inhibition and reduces protein synthesis and
cell proliferation. In addition, Sestrins decrease ROS generation
through the inhibition of NAPDH oxidase 4- (NOX4-) dependent
ROS generation pathway. 4EBP1: eukaryotic translation initiation
factor 4E-binding protein 1; ATG1: autophagy-related protein 1;
S6K: ribosomal protein S6 kinase; TSC1/2: tuberous sclerosis
complex 1 and 2; ULK1: unc-51-like autophagy-activating kinase 1.
5
serves as a compensatory response to attenuate apoptosis
induced by various noxious stimuli. In contrast, downregu-
lation of Sestrin1/2 in cancerous cells causes accelerated
tumor cell growth [11, 46], which indicates that Sestrins
elicit proapoptotic effects in cancer cells. Thus, Sestrin2
could serve as a biomarker and a therapeutic target in vari-
ous diseases such as cardiovascular and metabolic disorders,
neurodegenerative diseases, and cancer.
5. Significance of Sestrins in Diseases
Based on the mounting evidences from the literature, it is
evident that Sestrins get upregulated in response to stress
stimuli (such as oxidative stress, genotoxic stress, ER stress,
and hypoxia), and they exert cytoprotective actions via
modulation of various cell signaling processes including
nutrient sensing, autophagy, and apoptosis. Hence, Sestrins
are implicated to play a protective role in various diseases
including cardiovascular and metabolic disorders, neurode-
generative diseases, and cancer.
5.1. Significance of Sestrins in Cardiovascular Diseases.
Increased cardiac load or damage leads to cardiac hypertro-
phy, which ultimately contributes to the malnutrition and
death of cardiomyocytes. Indeed, cardiac hypertrophy is
one predictor of mortality and morbidity associated with
cardiovascular diseases. Sestrins appear to play a role in
augmenting the antioxidant status within cells [5]. Because
oxidative stress is a major player in cardiac pathophysiology,
it was expected that Sestrins may be protective in cardiomy-
opathies. Mechanistically, it was found out that loss of Sestrin
results in mTOR hyperactivation, associated with decreased
cardiac function, and that inhibition of mTOR rescues the
deranged phenotype resulting from Sestrin downregulation
[14]. This is in line with earlier studies showing that Sestrin1
effectively suppresses angiotensin II-induced proliferation of
cardiac fibroblasts by its ability to inhibit mTOR signaling
[14]. Indeed, inhibiting mTOR appears to be cardioprotec-
tive especially under stressful conditions such as those result-
ing from pressure overload [15, 48].
Another mechanism by which Sestrin appears to affect
cardiac function is via its modulation of autophagic path-
ways. Tight regulation of autophagy may be beneficial in pro-
tecting against pressure overload cardiac hypertrophy [49].
On the contrary, blocking autophagy may further aggravate
the hypertrophic phenotype [16]. Knockdown of Sestrin1
exacerbates phenylephrine-induced hypertrophy of cardio-
myocytes, whereas its overexpression protects these cells
from hypertrophic stress [16]. Sestrin1 appears to elicit this
effect via activating the AMPK/mTORC1/autophagy axis,
and blockade of this pathway has been shown to reduce the
Sestrin’s ability to protect against hypertrophic stressors
[16]. Furthermore, the activation of AMPK through its
upstream kinase liver kinase B1 (LKB1) was demonstrated
to be essential for the maintenance and enhancement of
autophagic activity by Sestrin2 [8]. Consequently, the activa-
tion of AMPK controls mitochondrial biogenesis and
conserves the energy balance and, eventually, helps cells to
survive under ischemic conditions.
Sestrins also appear to play a beneficial role in atheroscle-
rosis. Indeed, it was recently shown that knockdown of
Sestrin2 potentiates the formation of atherosclerotic plaques
and other hallmarks of atherosclerosis in mice [50]. The
underlying mechanism for this effect appears to involve
increased ROS production and ER stress as well as increased
adhesion molecules in the vasculature [50]. Taken together,
Sestrins 1 and 2 may prove to be attractive targets for amelio-
ration of cardiovascular diseases.
5.2. Significance of Sestrins in Metabolic Disorders.Metabolic
disorders such as diabetes and obesity are marked by alter-
ations in the principal nutrient-sensing mechanisms AMPK
and mTOR and are associated with an increased risk of
cardiovascular diseases and stroke [21, 37, 38]. Chronic activa-
tion of mTORC1 during overnutrition increases protein and
lipid synthesis and represses autophagic catabolism in cells
[23, 51]. One of the prominent negative feedback mechanisms
to circumvent the harmful effects of chronic mTORC1 activa-
tion is the transcriptional activation of Sestrin2. Upon activa-
tion, Sestrin2 activates AMPK signaling, which in turn
attenuates the activation of mTORC1 and, thus, secondarily
stimulates autophagy in cells [9, 23]. For example, a study by
Lee et al. [23] demonstrated that Sestrin2 was upregulated in
various tissues such as muscle, liver, and adipose tissues in a
mice model of type 2 diabetes and obesity. Similarly, Kimball
et al. [52] also showed the upregulation of Sestrin2 expression
in the livers of rats fed with a high-fat diet.
Chronic mTORC1 stimulation along with persistent
inhibition of autophagy in hepatocytes leads to insulin
resistance and type 2 diabetes mainly via inhibition of the
phosphorylation of insulin receptor substrates (IRSs) [53].
Chai et al. [25], in a study, demonstrated that insulin upregu-
lates Sestrin2 in mouse primary hepatic cells and hepatic
tumor cell lines. The upregulation of Sestrin2 expression by
insulin was demonstrated to be mediated through PI3K/
PKB/mTOR signaling pathway. Thus, it is evident that a
molecular loop exists between insulin and Sestrin2 during
chronic activation of mTORC1, and further studies to under-
stand the intricate feedback that exists between insulin and
Sestrin2 would give us insights to develop novel therapeutic
strategies to treat metabolic disorders [25].
5.3. Significance of Sestrins in Neurodegenerative Disorders.
Increased ROS levels damage neurons by overwhelming the
natural antioxidant defense mechanism, which ultimately
induces apoptosis. Thus, one of the effective strategies to treat
neurodegenerative diseases such as Parkinson’s disease (PD)
and Alzheimer’s disease (AD) is to protect neuronal cells
from oxidative injury. Since Sestrin2 inhibits the generation
and accumulation of ROS, its effects are most useful in the
prevention and treatment of neurodegeneration and various
age-related disorders [19, 24].
The ability of Sestrin2 to inhibit mTORC1 and indirectly
activate autophagy is another mechanism that is most useful
in treating neurodegenerative diseases. For instance, dysreg-
ulation of the autophagy-lysosomal pathway is one of the
key mechanisms responsible for the accumulation of α-
synuclein, a major component of Lewy bodies observed in
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the brain of patients with PD. Using an in vitro model of PD,
Hou et al. [19] showed that the upregulation of Sestrin2 trig-
gers autophagic response and subsequently prevents α-synu-
clein expression, apoptotic caspase-3 activation, and
cytotoxicity in dopaminergic cells. Intriguingly, the observed
neuroprotection was attenuated following siRNA-mediated
genetic silencing of Sestrin2 expression, which indicates the
protective role of Sestrin2 against neurodegeneration. In
corroboration to these findings, Zhou et al. [54] reported
the upregulation of Sestrin2 in the midbrain of patients
with PD. Additional in vitro studies using 1-methyl-4-
phenylpyridinium- (MPP+-) inducedneurotoxicity in human
neuroblastoma SH-SY5Y cells by the same investigators
unveiled an induction of Sestrin2 mRNA and protein levels
via activation of p53-mediated pathway. Moreover, knock-
down of Sestrin2 intensified MPP+-induced neurotoxicity.
Similar to the findings obtained from the experimental
models of PD, using an in vitro model of AD, Chen et al. [20]
identified Sestrin2 as one of the target genes that was induced
upon exposure to amyloid beta (Aβ) peptide in human neuro-
blastoma cells. Knockdown of Sestrin2 was shown to abrogate
autophagic response and aggravate Aβ-induced neurotoxic-
ity. Although the exact mechanisms by which Sestrin2
modulates autophagic response and suppresses Aβ-induced
neurotoxicity in AD is yet to be evaluated, the defensive role
of Sestrin2 against neurodegeneration makes it a positive
prognostic marker and a pharmacological target in neurode-
generative diseases.
5.4. Significance of Sestrins in Cancer. Increased production
and accumulation of ROS and the resultant alterations in
cellular redox status in tumor cells favors genomic insta-
bility and allows subsequent mutations to support tumor
progression [55]. Moreover, in an advanced stage, cancer
cells recurrently show high levels of ROS, which facilitates
tumor metastasis [55]. Thus, inhibition of ROS generation
might serve as a viable strategy to inhibit the progression
of cancer. Sestrin2, a novel p53-dependent stress-inducible
protein, which gets activated under hypoxic conditions, is
downregulated in cancer cells [11, 46]. Similarly, deficiency
of Sestrin2 in mouse embryonic fibroblasts was associated
with the increased expression of cyclin D1 (a cell cycle regu-
lator) and increased Ras-activated tumor cell growth com-
pared to wild type cells [9].
Most cancer cells induce the expression of HIF-1α for their
survival in a hypoxic tumor microenvironment [55]. Thus,
inhibition of HIF-1α expression is deemed as an effective strat-
egy to inhibit the progression and metastases of tumor cells. In
this regard, a study by Seo et al. [4] demonstrated that the over-
expression of Sestrin2 represses the accumulation of HIF-1α (a
key transcription factor involved in tumorigenesis and
hypoxia-dependent gene transcription) and prevents the
metastasis of colorectal cancer. Besides, the study also revealed
the involvement of AMPK in Sestrin2-mediated degradation of
HIF-1α through the upregulation of prolyl-4-hydroxylases
(PHD) and targeted hydroxylation of HIF-1α. Furthermore,
knockdown of AMPK via siRNA prevented the inhibitory
actions of Sestrin2 on HIF-1α accumulation. Collectively, it
could be concluded that Sestrin2 acts as a negative regulator
of tumor progression via an AMPK-dependent mechanism.
The significance of mTOR hyperactivation leading to
tumorigenesis and tumor progression is well documented
[37]. mTOR activation-induced protein synthesis also leads
to unfolded protein response, which if unresolved, results in
sustained ER stress and ultimately causes tissue injury [31].
Thus, as a negative regulator of mTOR, it is expected that Ses-
trin2 could serve as a biomarker and a therapeutic target in
cancer. In support to this notion, a study by Ro et al. [22]
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Figure 4: Protective effects of Sestrins in cardiovascular diseases, metabolic disorders, neurodegenerative diseases, and cancer. The
antioxidant effects of Sestrins are primarily responsible for their protective effects against neurodegenerative diseases and other disease
states associated with significant accumulation of ROS. Additionally, by modulating mTOR/AMPK signaling pathway by Sestrin2
indirectly represses tumor growth and activates autophagy. Consequently, autophagy activation confers a protective role of metabolic and
heart diseases and aging. ATG1/13: autophagy-related protein 1 and 13; mTOR: mammalian target of rapamycin.
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demonstrated that treatment with 5-fluorouracil (5FU)
induces the expression of Sestrin2, which in turn represses
the in vitro migration of colon cancer cell lines such as
HCT116 and HT29 cells. Recent studies by Seo et al. [56] in
colon cancer cells also reveal that 5FU-mediated induction of
Sestrin2 occurs through p53-dependent pathway.
Growing body of evidences from numerous cancer cell
lines highlights the role of Sestrin2 in the regulation of cell
growth and proliferation in cancer [9, 11, 12, 22]. A study by
Budanov and Karin [9] in mouse embryonic fibroblasts
(MEFs) reported that Sestrin2 inhibits cellular proliferation
via reducing the transcription of cyclin D1 (a cell cycle regula-
tor) and c-Myc (an oncogene). In addition, the study also dem-
onstrated that knockdown of Sestrin2 renders MEF cells prone
to Ras-activated oncogenic transformation. Consistent with
these findings, a study in lung cancer cells by Ding et al. [11]
reported that deficiency of Sestrin2 promotes migration of
cancer cells in vitro and growth of xenograft tumors in vivo.
A recent study in nonsmall cell lung cancer (NSCLC) by
Chen et al. [12] revealed that significant downregulation of
Sestrin2 in the aggressive NSCLC including tumor, node,
metastasis (TNM) stage and lymph node metastasis. Multi-
variate analyses of the results indicated an inverse relation-
ship between the levels of Sestrin2 and the progression of
NSCLC. Similarly, genetic deletion of Sestrin2 in mice was
demonstrated to exhibit increased propensity to develop
colon cancer [22]. Clinical evidence from colon cancer
patients showing downregulation of Sestrin2 and a negative
correlation between Sestrin2 levels and resistance to chemo-
therapy further supports the notion that Sestrin2 acts a
tumor-suppressive protein and serves as a surrogate prog-
nostic marker in multiple cancers such as NSCLC and colon
cancer. The key signaling mechanisms that are modulated by
Sestrin2 and how it exerts its protective effects in various
disease states are shown in the Figure 4.
6. Conclusion
Sestrin2, a stress-responsive protein, which is mainly regu-
lated by p53, exerts cytoprotective effects against genotoxic
and oxidative stress.More importantly, Sestrin2 is now recog-
nized as a key regulator of cell metabolism and an active con-
tributor to cellular homeostasis in normal physiology and
diseased states. Its potent antioxidant effects are shown to
confer neuroprotection in neurodegenerative disorders that
are closely linked to oxidative stress such as Parkinson’s dis-
ease and Alzheimer’s disease. As a positive regulator of
AMPK and a repressor of mTORC1, Sestrins elicit protective
effects in various metabolic disorders such as diabetes and
obesity, cancer, cardiac hypertrophy, and atherosclerosis as
shown in the Figure 5. Thus, Sestrins demonstrate tremen-
dous potential to serve as a favorable prognostic marker and
a viable therapeutic target in various diseases.
To devise therapeutic strategies to upregulate Sestrins, it is
important to decipher both the upstream and downstream
pathways that underlie Sestrin’s pleiotropic beneficial effects
such as antioxidant effects, abrogation of hypoxic signaling
and ER stress, AMPK activation/mTORC1 inhibition, autoph-
agy activation, prosurvival effects on normal cells, and anti-
proliferative effects on cancer cells. Future studies using
transgenic animal models with conditional, organ-specific
knockout of Sestrin2 and attempts to correlate the levels
of Sestrin2 (in patients’ biopsy samples) with disease pro-
gression would help us to identify the biochemical pathways
that are modulated by Sestrin2 in specific diseases. Further-
more, development and screening of small molecule Sestrin2
mimetics or inducers using in vitro and in vivo models would
be helpful to ascertain the therapeutic potential of Sestrin2 as a
drug target in various diseases.
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